While some pharmacy benefit managers (PBMs) have been talking about transparency for years, it has become an increasingly hot topic in the health care industry. So what does transparency really mean? Let’s take a fast five (minutes) to look at PBM pricing models and how transparency comes into play.
Everyone is hearing a lot about prescription drug pricing lately thanks to a very famous billionaire entrepreneur. What is cost-plus pricing? Is it new? How is it disrupting the industry? In this Fast Five, we share answers to these questions and provide guidance on how to evaluate this model. For a smart insider’s perspective, we consulted with Sharon Faust, Senior Vice President, Lumicera Specialty Pharmacy.
Making a pharmacy benefit manager (PBM) transition can be a daunting task especially for busy benefit teams. We consulted our internal implementation experts on what a smooth transition looks like and how the right partner will provide reassurance that you are making the right move.
Biosimilars are a hot topic in the pharmacy industry right now. Wondering what all the buzz is about? In this Fast Five, we asked our clinical experts, Janelle Sheen and Imke Scheepers, to share the basics about biosimilars as well as some key insights on this topic.
Our Vice President of Sales, Jonathan Har-Even, shares his outlook on the industry and where we need to go next. He discusses 5 ways the PBM industry can continue to improve and promote better healthcare for all, including a 5-year plan that uses lowest net cost as a foundation and builds out a platform for payors, members, and pharmacists.
Check out this insightful article published in JMCP on these challenges and the implications for plan sponsors working for a sustainable drug benefit.
Does your PBM provide transparent contracts and reporting? It is time to move PBM business intelligence out of the dark ages. This white paper is the third in a series dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Is your PBM applying rigorous clinical criteria to effectively identify and remove waste in your specialty drug benefit? Learn how misaligned coverage models and weak clinical criteria are working against plan sponsors. This white paper is the second of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Are your PBM's financial interests fully aligned with yours? Learn more about the inherent financial conflicts found in traditional PBM business models. This white paper is the first of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Update your browser to view this website correctly. Update my browser now